Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Yu-Yang Liu, Yi-Yang Qu, Shang Wang, Ci-Jun Luo, Hong-Ling Qiu, Hui-Ting Li, Ping Yuan, Lan Wang, Jin-Ling Li, Rong Jiang, Rui Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Subjects:	pulmonary arterial hypertension riociguat systematic review meta, analysis phosphodiesterase-5 inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1155631/full

Similar Items

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-01-01)

Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin
by: Qingqing Li, et al.
Published: (2024-09-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z S Valieva, et al.
Published: (2018-04-01)

Meta‐Analysis of Real‐World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension
by: Esra Pamukçu, et al.
Published: (2025-02-01)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
by: Humberto García Aguilar, et al.
Published: (2022-07-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017-04-01)

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
by: E. A. Devetyarova, et al.
Published: (2018-06-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Better efficacy of sequential combination with balloon pulmonary angioplasty after long‐term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension
by: Wei Wang, et al.
Published: (2024-07-01)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
by: Mihalek AD, et al.
Published: (2022-10-01)

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
by: Katharina Nubbemeyer, et al.
Published: (2025-04-01)

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
by: E. V. Filippov
Published: (2020-12-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
by: S. A. Musashaykhova, et al.
Published: (2022-12-01)

Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation
by: Yousuf M. Al Suleimani, et al.
Published: (2025-10-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Effect of Riociguat on Adenine-Induced Chronic Kidney Disease in Rats
by: Aly M. Abdelrahman, et al.
Published: (2025-02-01)

Results of long-term riociguat therapy, including a switching strategy from sildenafil, in patients with pulmonary hypertension of various genesis
by: S. A. Musashaykhova, et al.
Published: (2023-11-01)

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry
by: Pavel Jansa, et al.
Published: (2021-06-01)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
by: Erin M. Schikowski, et al.
Published: (2022-11-01)

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide
by: L. T. Domingo, et al.
Published: (2022-12-01)

Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats
by: Raya Al-Maskari, et al.
Published: (2024-12-01)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
by: Alberto M. Marra, et al.
Published: (2018-12-01)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
by: Tatsuo Aoki, et al.
Published: (2020-08-01)

THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
by: O. Ya. Vasiltseva, et al.
Published: (2019-12-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01)

Modulation of Second Messenger Signaling in the Brain Through PDE4 and PDE5 Inhibition: Therapeutic Implications for Neurological Disorders
by: Min Kyu Park, et al.
Published: (2025-01-01)

Expert consensus on approaches to risk stratification and choice of therapy in patients with inoperable and residual chronic thromboembolic pulmonary hypertension
by: Irina E. Chazova, et al.
Published: (2025-01-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

Inhibition of PDE‐4 isoenzyme attenuates frequency and overall contractility of agonist‐evoked ureteral phasic contractions
by: Iris Lim, et al.
Published: (2024-02-01)

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
by: N A Tsareva, et al.
Published: (2017-09-01)

PDE4-Mediated cAMP Signalling
by: Bracy A. Fertig, et al.
Published: (2018-01-01)

PDE4 inhibitors: potential protective effects in inflammation and vascular diseases
by: Tianfei Fan, et al.
Published: (2024-06-01)

Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region
by: Chloe Gulliver, et al.
Published: (2023-10-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
by: GAO Luyang, et al.
Published: (2023-09-01)

Modern possibilities of echocardiographic diagnosis in pulmonary arterial hypertension
by: A. A. Klimenko, et al.
Published: (2025-01-01)

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
by: Franziska Elena Herrmann, et al.
Published: (2023-05-01)

The evolution and structure of snake venom phosphodiesterase (svPDE) highlight its importance in venom actions
by: Cheng-Tsung Pan, et al.
Published: (2023-04-01)